Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Moderate to severe RA according to 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) joint criteria
Treatment with tocilizumab SC monotherapy for up to 8 weeks prior to enrollment, under the prescriptive authority of a physician who has made the decision to commence tocilizumab in accordance with the local label
Methotrexate intolerance, or inadequate response to prior DMARDs and TNF inhibitors where continued methotrexate treatment was deemed inappropriate
You may not be if
Treatment with tocilizumab more than 8 weeks prior to enrollment
Failure to meet local tocilizumab label indication criteria
Treatment with any investigational agent within 4 weeks of beginning tocilizumab SC monotherapy
Last methotrexate dose within 1 week of beginning tocilizumab SC monotherapy
History of any other autoimmune or joint inflammatory disease
Clareo Health | Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)
